{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:15:42Z","timestamp":1790878542695,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010293","name":"Seattle Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cluster of differentiation 70 (CD70) is frequently expressed in renal cell carcinoma (RCC) and has immunomodulatory properties. An antibody\u2010drug conjugate targeting CD70, SGN\u2010CD70A, was developed to treat patients with CD70\u2010positive RCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The objective of this phase 1, open\u2010label, dose\u2010escalation, multicenter study was to evaluate the safety and tolerability of SGN\u2010CD70A and establish its maximum tolerated dose in patients with CD70\u2010positive, metastatic RCC (mRCC). All subtypes of RCC were permitted, and no limit was set on the number of prior therapies. Safety assessments consisted of monitoring and recording all adverse events (AEs) and dose\u2010limiting toxicities (DLTs). Treatment response was assessed by radiographic tumor evaluation according to the Response Evaluation Criteria for Solid Tumors, version 1.1. A model\u2010based, modified continual\u2010reassessment method was used to estimate the probabilities of DLT and response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The maximum tolerated dose was determined to be 30 \u03bcg\/kg, with thrombocytopenia as the DLT. The most common AEs were fatigue (67%), anemia (61%), and thrombocytopenia (56%). Of 18 enrolled patients, 1 achieved a partial response and 13 achieved stable disease, for a clinical benefit rate of 78%. Limitations of the study included the heavily pretreated nature of patients, receipt of a median of 4 prior lines of therapy (range, 1\u20108 prior lines of therapy), and diminishing response potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The modest antitumor activity of SGN\u2010CD70A does not support its development in mRCC. However, given the high disease control rate in a heavily pretreated population and the modest toxicity profile, CD70 remains of interest because of its immunomodulatory properties.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31912","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T09:09:20Z","timestamp":1547024960000},"page":"1124-1132","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["A phase 1 trial of SGN\u2010CD70A in patients with CD70\u2010positive, metastatic renal cell carcinoma"],"prefix":"10.1002","volume":"125","author":[{"given":"Sumanta K.","family":"Pal","sequence":"first","affiliation":[{"name":"Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero\u2010Torres","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Clinical Oncology University of Alabama at Birmingham Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance\/University of Washington Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[{"name":"University of Cincinnati Cancer Institute Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"Hollings Cancer Center Medical University of South Carolina Charleston South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Hoimes","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Case Western Reserve University Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Vogelzang","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Centers of Nevada Las Vegas Nevada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boyd","sequence":"additional","affiliation":[{"name":"North Star Lodge Cancer Care Center, Yakima Valley Memorial Hospital Yakima, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo G.","family":"Bergerot","sequence":"additional","affiliation":[{"name":"Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Adashek","sequence":"additional","affiliation":[{"name":"Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Yu","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaina M.","family":"Gartner","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie","family":"Carret","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601333"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.029"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.578"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01573.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.05.005"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2883"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605816"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2791"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2647"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0655-0"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-011-9539-1"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70030-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113205"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.293"},{"issue":"2","key":"e_1_2_8_21_1","first-page":"O20","article-title":"Pivot\u201002: preliminary safety, efficacy and biomarker results from the phase 1\/2 study of CD\u2010122\u2010biased agonist NKTR\u2010214 plus nivolumab in patients with locally advanced\/metastatic solid tumors [abstract]","volume":"5","author":"Diab A","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.31912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:42:23Z","timestamp":1761867743000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/cncr.31912"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31912","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"2018-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}